Latest Trius Therapeutics (TSRX) Headlines Igny
Post# of 1
Posted On: 03/13/2014 3:02:10 PM
Latest Trius Therapeutics (TSRX) Headlines
Ignyta Appoints Matthew Onaitis as General Counsel
Business Wire - Mon Feb 03, 6:00AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Matthew Onaitis has been appointed to the newly created role of General Counsel and Secretary. Mr. Onaitis was previously Senior Vice President, General Counsel and Secretary of Trius Therapeutics, Inc., where he led the legal and compliance functions through Trius' acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Mr. Onaitis assisted Cubist with integration activities through December 2013. Prior to Trius, Mr. Onaitis was Senior Vice President, General Counsel and Secretary of Somaxon Pharmaceuticals, Inc. from 2006 until Somaxon's acquisition by Pernix Therapeutics Holdings, Inc. in March 2013. Mr. Onaitis also previously served as Associate General Counsel for the oncology strategic business unit of Biogen Idec Inc. and as Director of Legal Affairs of Elan Corporation, plc.
The Million-Dollar Volkswagen and 10b5-1 Plans
ACCESSWIRE - Mon Jan 13, 10:13AM CST
Dr. Jeff Stein, former President and CEO of Trius Therapeutics and former Chairman of the Antibiotics Working Group (AWG), today published a new blog post as a Key Opinion Leader on The Chairman's Blog. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market to 2016: Pfizer, Cubist, ViroPharma, Forest Labs Dominate
M2 - Tue Nov 05, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/nptv4k/global) has announced the addition of the "Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market to 2016" report to their offering. The Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market to grow at a CAGR of 3 percent over the period 2012-2016. The most common trend witnessed in the Global MRSA Drugs market is various governmental and non-governmental awareness programs that are informing people about the advanced treatments and educating people about the spread of infections. Moreover, vendors are supporting such comprehensive care programs through awareness campaigns for educating people about the spread and the treatment of infectious diseases.' According to the report, the increase in the prevalence of MRSA infections has increased the usage of drugs used against MRSA infection across the globe. Further, the report states that the rapid development of resistance to existing therapies is a major factor hampering the growth of the Global MRSA Drugs market. The key vendors dominating this market space are: - Pfizer Inc. - Cubist Pharmaceuticals Inc. - ViroPharma Inc. - Theravance Inc. - Forest Laboratories Inc. The other vendors mentioned in the report are: - Basilea Pharmaceutica Ltd. - Durata Therapeutics, Inc. - Novartis AG - Trius Therapeutics, Inc. - AstraZeneca plc. - GlaxoSmithKline plc. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Five Force Analysis 8. Geographical Segmentation 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/nptv4k/global
Cubist Pharmaceuticals Completes Acquisition of Optimer Pharmaceuticals
Business Wire - Thu Oct 24, 8:45AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today that it has completed its acquisition of Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) for an aggregate upfront cash consideration of approximately $551 million. Optimer stockholders approved the merger agreement at a special meeting of stockholders held on October 23, 2013. Effective today, Optimer common stock will cease to be traded on the NASDAQ.
Cubist Announces Submission of New Drug Application for Investigational Antibiotic Tedizolid for Treatment of Serious Skin Infections
Business Wire - Tue Oct 22, 7:30AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of its investigational antibiotic tedizolid phosphate (TR-701). Cubist is seeking approval of tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Tedizolid phosphate is a once daily oxazolidinone being developed for both intravenous (I.V.) and oral administration for the treatment of serious Gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
Former CEO of Trius Therapeutics Publishes New Blog Entitled "FDA Drug Approvals: Congress Giveth then Taketh Away"
ACCESSWIRE - Tue Oct 08, 10:46AM CDT
Former CEO of Trius Therapeutics, Dr. Jeffrey Stein, published a new blog post on The Chairman's Blog. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Cubist Pharmaceuticals Inc acquires Trius Therapeutics Inc for USD704m
M2 - Thu Sep 12, 8:47AM CDT
Biopharmaceutical company Cubist Pharmaceuticals Inc (NasdaqGS :CBST) revealed on Wednesday that it has completed the acquisition of Trius Therapeutics Inc (NasdaqGM:TSRX) for an aggregate upfront cash consideration of approximately USD704m.
Cubist Pharmaceuticals Completes Acquisition of Trius Therapeutics
Business Wire - Wed Sep 11, 3:30PM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has completed the previously announced acquisition of Trius Therapeutics, Inc. (NASDAQ: TSRX) for an aggregate upfront cash consideration of approximately $704 million. Effective today, Trius common stock will cease to be traded on the NASDAQ.
Cubist Pharmaceuticals Announces Results of Tender Offer for Outstanding Shares of Trius Therapeutics
Business Wire - Wed Sep 11, 10:00AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the results of Cubist's tender offer to purchase all of the outstanding common shares of Trius Therapeutics, Inc. (NASDAQ: TSRX) for $13.50 per share in cash, plus one Contingent Value Right, entitling the holder to receive an additional cash payment of up to $2.00 for each share they tender if certain commercial sales milestones are achieved. The tender offer is being effected by Cubist's subsidiary, BRGO Corporation. The tender offer period expired today, at 9:00 a.m. Eastern Time.
Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013
GlobeNewswire - Fri Sep 06, 3:01PM CDT
Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections, announced today that results of clinical studies of its lead antibiotic candidate, tedizolid phosphate, will be presented this week at the 53 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Denver. Seven poster and slide sessions regarding tedizolid have been accepted for presentation. Trius researchers will also present a poster on cfr resistance and two poster sessions on the company's GyrB/ParE antibacterial program, which targets Gram-negative pathogens.
Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2013
M2 - Fri Sep 06, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34mzvk/skin_and_skin) has announced the addition of the "Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2013" report to their offering. 'Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Skin And Skin Structure Infections (SSSI), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI). Scope - A snapshot of the global therapeutic scenario for Skin And Skin Structure Infections (SSSI). - A review of the Skin And Skin Structure Infections (SSSI) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Skin And Skin Structure Infections (SSSI) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Skin And Skin Structure Infections (SSSI) Therapeutics Development - GlaxoSmithKline plc - Rib-X Pharmaceuticals, Inc. - Paratek Pharmaceuticals, Inc. - Affinium Pharmaceuticals, Inc. - Bharat Biotech International Limited - Nabriva Therapeutics AG - Cempra Pharmaceuticals, Inc. - Trius Therapeutics, Inc. - Tetraphase Pharmaceuticals Inc. - Durata Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/34...n_and_skin
Pneumonia - Pipeline Review, H2 2013 Features Top Players Profiled
M2 - Tue Sep 03, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rzgnns/pneumonia) has announced the addition of the "Pneumonia - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Pneumonia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pneumonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pneumonia. Pneumonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Pneumonia. - A review of the Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pneumonia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some of the Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 APEPTICO Forschung und Entwicklung GmbH Aridis Pharmaceuticals LLC aRigen Pharmaceuticals, Inc. AstraZeneca PLC Basilea Pharmaceutica Ltd. Bayer AG Biotest AG Cubist Pharmaceuticals, Inc. Durata Therapeutics Inc. Flamel Technologies S.A. KYORIN Pharmaceutical Co., Ltd. KaloBios Pharmaceuticals, Inc. LTT Bio-Pharma Co., Ltd. Mucosis B.V. Paratek Pharmaceuticals, Inc. Pulmotect, Inc. Rib-X Pharmaceuticals, Inc. Sanofi-Aventis Savara, Inc. TaiGen Biotechnology Co., Ltd. Tetraphase Pharmaceuticals Inc. Toyama Chemical Co. Ltd Trius Therapeutics, Inc. Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/rzgnns/pneumonia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Daily Alert Stock Watch - Trius Therapeutics, Inc. (NASDAQ: TSRX)
WorldStockWire - Mon Sep 02, 10:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Cubist Receives Antitrust Clearance for Trius Purchase
Rich Duprey, The Motley Fool - Motley Fool - Thu Aug 29, 9:08PM CDT
The waiting period for Cubist Pharmaceuticals ' acquisition of Trius Therapeutics under the Hart-Scott-Rodino Antitrust Improvements Act, or HSR, expired on Aug. 29, the company announced today, allowing the transaction to move to the...
Cubist Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Trius
Business Wire - Thu Aug 29, 3:00PM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Trius Therapeutics, Inc. (NASDAQ: TSRX) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") in connection with Cubist's previously announced tender offer for all of the outstanding common stock of Trius.
Drug Innovations, Higher Margins and Improving Standards of Clinical Research - Research Report on Quest Diagnostics, Trius, WuXi, Quintiles, and ICON
PR Newswire - Thu Aug 15, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
SHAREHOLDER ALERT: Law Firm Brower Piven Announces That a Class Action Lawsuit Has Been Filed in Connection With the Trius Therapeutics, Inc. Proposed Buyout Alleging That Trius's Directors Have Breached Their Fiduciary Duties to Shareholders
GlobeNewswire - Wed Aug 14, 2:50PM CDT
The securities litigation firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been filed in the Delaware Chancery Court on behalf of all stockholders of Trius Therapeutics, Inc. ("Trius" or the "Company") (Nasdaq:TSRX) common stock.
Cubist Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Trius Therapeutics
Business Wire - Tue Aug 13, 3:00PM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the commencement of its tender offer for all outstanding shares of the common stock of Trius Therapeutics (NASDAQ: TSRX) for $13.50 per share in cash, plus one Contingent Value Right, entitling the holder to receive an additional cash payment of up to $2.00 for each share they tender if certain sales milestones are achieved. The tender offer is being made by BRGO Corporation, a wholly-owned subsidiary of Cubist, pursuant to the previously announced Agreement and Plan of Merger, dated July 30, 2013, for Cubist to acquire Trius.
The 10 Most Common Reasons People Visit Their Doctor
Sean Williams, The Motley Fool - Motley Fool - Sun Aug 11, 1:20PM CDT
With the full implementation of the individual portion of the Patient Protection and Affordable Care Act less than five months away, physicians and doctor's offices around the country should be bracing for what could be an influx of new patients....
How Could This 3-Way Deal Shake Up an Entire Industry?
Blogs @ The Motley Fool - Motley Fool - Thu Aug 08, 10:30AM CDT
With two simultaneous moves that have set the pharmaceutical world on fire, Cubist Pharmaceuticals has triumphantly announced its arrival on the global stage. The company has received takeover approval from the respective boards of Trius...
Ignyta Appoints Matthew Onaitis as General Counsel
Business Wire - Mon Feb 03, 6:00AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Matthew Onaitis has been appointed to the newly created role of General Counsel and Secretary. Mr. Onaitis was previously Senior Vice President, General Counsel and Secretary of Trius Therapeutics, Inc., where he led the legal and compliance functions through Trius' acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Mr. Onaitis assisted Cubist with integration activities through December 2013. Prior to Trius, Mr. Onaitis was Senior Vice President, General Counsel and Secretary of Somaxon Pharmaceuticals, Inc. from 2006 until Somaxon's acquisition by Pernix Therapeutics Holdings, Inc. in March 2013. Mr. Onaitis also previously served as Associate General Counsel for the oncology strategic business unit of Biogen Idec Inc. and as Director of Legal Affairs of Elan Corporation, plc.
The Million-Dollar Volkswagen and 10b5-1 Plans
ACCESSWIRE - Mon Jan 13, 10:13AM CST
Dr. Jeff Stein, former President and CEO of Trius Therapeutics and former Chairman of the Antibiotics Working Group (AWG), today published a new blog post as a Key Opinion Leader on The Chairman's Blog. TheChairmansBlog.com is an exclusive online media publication that provides key executive officers and key opinion leaders a unique platform to share insights about company and industry trends.
Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market to 2016: Pfizer, Cubist, ViroPharma, Forest Labs Dominate
M2 - Tue Nov 05, 10:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/nptv4k/global) has announced the addition of the "Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market to 2016" report to their offering. The Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs market to grow at a CAGR of 3 percent over the period 2012-2016. The most common trend witnessed in the Global MRSA Drugs market is various governmental and non-governmental awareness programs that are informing people about the advanced treatments and educating people about the spread of infections. Moreover, vendors are supporting such comprehensive care programs through awareness campaigns for educating people about the spread and the treatment of infectious diseases.' According to the report, the increase in the prevalence of MRSA infections has increased the usage of drugs used against MRSA infection across the globe. Further, the report states that the rapid development of resistance to existing therapies is a major factor hampering the growth of the Global MRSA Drugs market. The key vendors dominating this market space are: - Pfizer Inc. - Cubist Pharmaceuticals Inc. - ViroPharma Inc. - Theravance Inc. - Forest Laboratories Inc. The other vendors mentioned in the report are: - Basilea Pharmaceutica Ltd. - Durata Therapeutics, Inc. - Novartis AG - Trius Therapeutics, Inc. - AstraZeneca plc. - GlaxoSmithKline plc. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Five Force Analysis 8. Geographical Segmentation 9. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/nptv4k/global
Cubist Pharmaceuticals Completes Acquisition of Optimer Pharmaceuticals
Business Wire - Thu Oct 24, 8:45AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today that it has completed its acquisition of Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) for an aggregate upfront cash consideration of approximately $551 million. Optimer stockholders approved the merger agreement at a special meeting of stockholders held on October 23, 2013. Effective today, Optimer common stock will cease to be traded on the NASDAQ.
Cubist Announces Submission of New Drug Application for Investigational Antibiotic Tedizolid for Treatment of Serious Skin Infections
Business Wire - Tue Oct 22, 7:30AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of its investigational antibiotic tedizolid phosphate (TR-701). Cubist is seeking approval of tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Tedizolid phosphate is a once daily oxazolidinone being developed for both intravenous (I.V.) and oral administration for the treatment of serious Gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).
Former CEO of Trius Therapeutics Publishes New Blog Entitled "FDA Drug Approvals: Congress Giveth then Taketh Away"
ACCESSWIRE - Tue Oct 08, 10:46AM CDT
Former CEO of Trius Therapeutics, Dr. Jeffrey Stein, published a new blog post on The Chairman's Blog. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Cubist Pharmaceuticals Inc acquires Trius Therapeutics Inc for USD704m
M2 - Thu Sep 12, 8:47AM CDT
Biopharmaceutical company Cubist Pharmaceuticals Inc (NasdaqGS :CBST) revealed on Wednesday that it has completed the acquisition of Trius Therapeutics Inc (NasdaqGM:TSRX) for an aggregate upfront cash consideration of approximately USD704m.
Cubist Pharmaceuticals Completes Acquisition of Trius Therapeutics
Business Wire - Wed Sep 11, 3:30PM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it has completed the previously announced acquisition of Trius Therapeutics, Inc. (NASDAQ: TSRX) for an aggregate upfront cash consideration of approximately $704 million. Effective today, Trius common stock will cease to be traded on the NASDAQ.
Cubist Pharmaceuticals Announces Results of Tender Offer for Outstanding Shares of Trius Therapeutics
Business Wire - Wed Sep 11, 10:00AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the results of Cubist's tender offer to purchase all of the outstanding common shares of Trius Therapeutics, Inc. (NASDAQ: TSRX) for $13.50 per share in cash, plus one Contingent Value Right, entitling the holder to receive an additional cash payment of up to $2.00 for each share they tender if certain commercial sales milestones are achieved. The tender offer is being effected by Cubist's subsidiary, BRGO Corporation. The tender offer period expired today, at 9:00 a.m. Eastern Time.
Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013
GlobeNewswire - Fri Sep 06, 3:01PM CDT
Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections, announced today that results of clinical studies of its lead antibiotic candidate, tedizolid phosphate, will be presented this week at the 53 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Denver. Seven poster and slide sessions regarding tedizolid have been accepted for presentation. Trius researchers will also present a poster on cfr resistance and two poster sessions on the company's GyrB/ParE antibacterial program, which targets Gram-negative pathogens.
Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2013
M2 - Fri Sep 06, 9:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/34mzvk/skin_and_skin) has announced the addition of the "Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2013" report to their offering. 'Skin And Skin Structure Infections (SSSI) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Skin And Skin Structure Infections (SSSI), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI). Scope - A snapshot of the global therapeutic scenario for Skin And Skin Structure Infections (SSSI). - A review of the Skin And Skin Structure Infections (SSSI) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Skin And Skin Structure Infections (SSSI) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Skin And Skin Structure Infections (SSSI) Therapeutics Development - GlaxoSmithKline plc - Rib-X Pharmaceuticals, Inc. - Paratek Pharmaceuticals, Inc. - Affinium Pharmaceuticals, Inc. - Bharat Biotech International Limited - Nabriva Therapeutics AG - Cempra Pharmaceuticals, Inc. - Trius Therapeutics, Inc. - Tetraphase Pharmaceuticals Inc. - Durata Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/34...n_and_skin
Pneumonia - Pipeline Review, H2 2013 Features Top Players Profiled
M2 - Tue Sep 03, 9:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rzgnns/pneumonia) has announced the addition of the "Pneumonia - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Pneumonia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pneumonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pneumonia. Pneumonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Pneumonia. - A review of the Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pneumonia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Some of the Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 APEPTICO Forschung und Entwicklung GmbH Aridis Pharmaceuticals LLC aRigen Pharmaceuticals, Inc. AstraZeneca PLC Basilea Pharmaceutica Ltd. Bayer AG Biotest AG Cubist Pharmaceuticals, Inc. Durata Therapeutics Inc. Flamel Technologies S.A. KYORIN Pharmaceutical Co., Ltd. KaloBios Pharmaceuticals, Inc. LTT Bio-Pharma Co., Ltd. Mucosis B.V. Paratek Pharmaceuticals, Inc. Pulmotect, Inc. Rib-X Pharmaceuticals, Inc. Sanofi-Aventis Savara, Inc. TaiGen Biotechnology Co., Ltd. Tetraphase Pharmaceuticals Inc. Toyama Chemical Co. Ltd Trius Therapeutics, Inc. Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/rzgnns/pneumonia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
OTC Daily Alert Stock Watch - Trius Therapeutics, Inc. (NASDAQ: TSRX)
WorldStockWire - Mon Sep 02, 10:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Cubist Receives Antitrust Clearance for Trius Purchase
Rich Duprey, The Motley Fool - Motley Fool - Thu Aug 29, 9:08PM CDT
The waiting period for Cubist Pharmaceuticals ' acquisition of Trius Therapeutics under the Hart-Scott-Rodino Antitrust Improvements Act, or HSR, expired on Aug. 29, the company announced today, allowing the transaction to move to the...
Cubist Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of Trius
Business Wire - Thu Aug 29, 3:00PM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) and Trius Therapeutics, Inc. (NASDAQ: TSRX) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") in connection with Cubist's previously announced tender offer for all of the outstanding common stock of Trius.
Drug Innovations, Higher Margins and Improving Standards of Clinical Research - Research Report on Quest Diagnostics, Trius, WuXi, Quintiles, and ICON
PR Newswire - Thu Aug 15, 7:00AM CDT
Editor Note: For more information about this release, please scroll to bottom.
SHAREHOLDER ALERT: Law Firm Brower Piven Announces That a Class Action Lawsuit Has Been Filed in Connection With the Trius Therapeutics, Inc. Proposed Buyout Alleging That Trius's Directors Have Breached Their Fiduciary Duties to Shareholders
GlobeNewswire - Wed Aug 14, 2:50PM CDT
The securities litigation firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been filed in the Delaware Chancery Court on behalf of all stockholders of Trius Therapeutics, Inc. ("Trius" or the "Company") (Nasdaq:TSRX) common stock.
Cubist Pharmaceuticals Commences Tender Offer for All Outstanding Shares of Trius Therapeutics
Business Wire - Tue Aug 13, 3:00PM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced the commencement of its tender offer for all outstanding shares of the common stock of Trius Therapeutics (NASDAQ: TSRX) for $13.50 per share in cash, plus one Contingent Value Right, entitling the holder to receive an additional cash payment of up to $2.00 for each share they tender if certain sales milestones are achieved. The tender offer is being made by BRGO Corporation, a wholly-owned subsidiary of Cubist, pursuant to the previously announced Agreement and Plan of Merger, dated July 30, 2013, for Cubist to acquire Trius.
The 10 Most Common Reasons People Visit Their Doctor
Sean Williams, The Motley Fool - Motley Fool - Sun Aug 11, 1:20PM CDT
With the full implementation of the individual portion of the Patient Protection and Affordable Care Act less than five months away, physicians and doctor's offices around the country should be bracing for what could be an influx of new patients....
How Could This 3-Way Deal Shake Up an Entire Industry?
Blogs @ The Motley Fool - Motley Fool - Thu Aug 08, 10:30AM CDT
With two simultaneous moves that have set the pharmaceutical world on fire, Cubist Pharmaceuticals has triumphantly announced its arrival on the global stage. The company has received takeover approval from the respective boards of Trius...
(0)
(0)Trius Therapeutics (TSRX) Stock Research Links
Scroll down for more posts ▼